14-day Premium Trial Subscription Try For FreeTry Free
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of IMMU.ST
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Immunicum AB (publ) stock price down 0.445% on Friday
(Updated on May 17, 2024)

Sell candidate since May 14, 2024 Loss -4.89% PDF

The Immunicum AB (publ) stock price fell by -0.445% on the last day (Friday, 17th May 2024) from kr0.449 to kr0.447. During the last trading day the stock fluctuated 4.54% from a day low at kr0.430 to a day high of kr0.449. The price has been going up and down for this period, and there has been a -3.77% loss for the last 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -2 million shares and in total, 1 million shares were bought and sold for approximately kr609.18 thousand.

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -3.94% during the next 3 months and, with a 90% probability hold a price between kr0.408 and kr0.501 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

IMMU.ST Signals & Forecast

A buy signal was issued from a pivot bottom point on Wednesday, May 15, 2024, and so far it has fallen 0%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Immunicum AB (publ) stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at kr0.458 and kr0.478. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Support, Risk & Stop-loss for Immunicum AB (publ) stock

Immunicum AB (publ) finds support from accumulated volume at kr0.440 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the stock moved kr0.0195 between high and low, or 4.54%. For the last week the stock has had daily average volatility of 6.75%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (IMMU.ST) For The Upcoming Trading Day Of Monday 20th

For the upcoming trading day on Monday, 20th we expect Immunicum AB (publ) to open at kr0.442, and during the day (based on 14 day Average True Range), to move between kr0.418 and kr0.476, which gives a possible trading interval of +/-kr0.0291 (+/-6.52%) up or down from last closing price. If Immunicum AB (publ) takes out the full calculated possible swing range there will be an estimated 13.03% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at kr0.440 (1.68%) than the resistance at kr0.477 (6.60%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Immunicum AB (publ) stock A Buy?

Immunicum AB (publ) holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -2.902 Sell Candidate Unchanged

Predicted Opening Price for Immunicum AB (publ) of Monday, May 20, 2024

Fair opening price May 20, 2024 Current price
kr0.442 ( 1.16%) kr0.447

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for IMMU.ST

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 0.461 3.21 %
R2 0.454 1.54 %
R1 0.449 0.511 %
Current price: 0.447
Support S1 0.434 -2.82 %
S2 0.430 -3.85 %
S3 0.422 -5.52 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0.500 11.86 %
R2 0.491 9.73 %
R1 0.477 6.60 %
Current price 0.447
Support S1 0.440 -1.68%
S2 0 .
S3 0 .

FAQ

What is the symbol for Immunicum AB (publ) Stock and on which exchange is it traded?
The symbol for Immunicum AB (publ) is IMMU.ST and it is traded on the OMX (Stockholm Stock Exchange).

Should I buy or sell Immunicum AB (publ) Stock?
Immunicum AB (publ) holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Immunicum AB (publ) Stock?
Immunicum AB (publ) Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Immunicum AB (publ) Stock.

What's the current price of Immunicum AB (publ) Stock?
As of the end of day on the May 17, 2024, the price of an Immunicum AB (publ) (IMMU.ST) share was kr0.447.

What is the 52-week high and low for Immunicum AB (publ) Stock?
The 52-week high for Immunicum AB (publ) Stock is kr1.62 and the 52-week low is kr0.300.

What is the market capitalization of Immunicum AB (publ) Stock?
As of the May 17, 2024, the market capitalization of Immunicum AB (publ) is 450.214M.

When is the next earnings date for Immunicum AB (publ)?
The upcoming earnings date for Immunicum AB (publ) is May 18, 2024.
Click to get the best stock tips daily for free!

About Immunicum AB (publ)

Immunicum AB (publ) Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid... IMMU.ST Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT